The Evaluation and Treatment of Neuroleptic-Induced Movement Disorders

References

• Burke RE, Kang UJ, Jankovic J. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989; 4: 157–75
   PubMed Web of Science ®Google Scholar
• Gardos G, Cole JO, Salomon M, Schniebolk S. Clinical forms of severe tardive dyskinesia. Am J Psychiatry 1987; 144: 895–902
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner M, Borenstein M. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254–8
   PubMedGoogle Scholar
• Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir J M J, Bergmann KJ, et al. Prospective study of tardive dyskinesia in the elderly. JAMA 1991; 266: 2402–6
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner M, Sarantakos-Kinon B, Lieberman J. Do low dose neuroleptics prevent or ameliorate tardive dyskinesia?. Tardive dyskinesia and neuroleptics: from dogma to reason, DE Casey, G Gardos. American Psychiatric Press, Washington, DC 1986; 99–108
   Google Scholar
• Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978; 135: 1321–4
   PubMed Web of Science ®Google Scholar
• Kane JM. Tardive dyskinesia. A task force report of the American Psychiatric Association. American Psychiatric Press, Washington, DC 1992
   Google Scholar
• Adler L, Angrist B, Peselow E, Corwin J, Rotrosen J. Efficacy of propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1985; 5: 164–6
   Google Scholar
• Barnes T R E, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874–8
   PubMedGoogle Scholar
• Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol 1983; 3: 235–6
   PubMed Web of Science ®Google Scholar
• Wojcik JD, Falk WE, Fink JS, Cole JO, Gelenberg AJ. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991; 148: 1055–9
   PubMed Web of Science ®Google Scholar
• Burke RE, Kang UJ. Tardive dystonia: clinical aspects and treatment. Facial dyskinesias, J Jankovic, E Tolosen. Raven, New York 1988; 199–210
   Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacologyRevised ed. Department of Health, Education, and Welfare, Washington, DC 1976
   Google Scholar
• Gardos G, Cole JO, Labrie R. The assessment of tardive dyskinesia. Arch Gen Psychiatry 1977; 34: 1206–12
   PubMed Web of Science ®Google Scholar
• Schooler NR, Kane JM. Research diagnosis for tardive dyskinesias. Arch Gen Psychiatry 1982; 9: 486–7
   Google Scholar
• Barnes T R E. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6
   PubMed Web of Science ®Google Scholar
• Cunningham SL, Dorsey CM, Richardson GS, Winkelman JW, Lucas SE, Fortin MB. An objective marker for neuroleptic-induced akathisia: preliminary measures of sensitivity and specificity [Abstract]. Sleep Res 1992; 21: 53
   Google Scholar
• Gardos G, Teicher MH, Lipinski JF, Matthews JD, Morrison L, Conley C, et al. Quantitative assessment of psychomotor activity in patients with neuroleptic-induced akathisia. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 27–37
   Google Scholar
• Yassa R, Jones BD. The complications of tardive dyskinesia. Psychosomatics 1985; 26: 305–13
   PubMed Web of Science ®Google Scholar
• Casey DE. Tardive dyskinesia. Psychopharmacology: the third generation of progress, HY Meltzer. Raven, New York 1987; 1411–9
   Google Scholar
• Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. Guilford, New York 1982
   Google Scholar
• Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol plus biperiden, thioridazine, and clozapine. Psychopharmacology 1978; 59: 105–12
   PubMedGoogle Scholar
• Meltzer HY. Clozapine and other atypical neuroleptics, efficacy, side effects, optimal utilization. Clin Psychiatry Monogr 1994; 12(2)38–42
   Google Scholar
• Baldessarini RJ, Frankenburg FR. Clozapine-a novel antipsychotic agent. N Engl J Med 1991; 325: 746–54
   Google Scholar
• Frankenburg FR, Zanarini MC. Uses of clozapine in nonschizophrenic patients. Harvard Rev Psychiatry 1994; 2: 142–50
   PubMed Web of Science ®Google Scholar
• Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994; 55(9 suppl B)107–9
   Google Scholar
• Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55(9 suppl B)102–6
   Google Scholar
• Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane JM. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10
   PubMed Web of Science ®Google Scholar
• Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP. Risperidone: efficacy and side effects. J Clin Psychiatry Monogr 1994; 12: 53–60
   Google Scholar
• Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry 1985; 46: 195–245
   Google Scholar
• Miller LG, Jankovic J. Drug-induced movement disorders: an overview. Movement disorders in neurology and neuropsychiatry, AB Joseph, RR Young. Blackwell Scientific, Boston 1992; 5–32
   Google Scholar
• Schradt GR, Wright JH, Simpson R, Moore DP, Chase S. Treatment of tardive dyskinesia with propranolol. J Clin Psychiatry 1982; 43: 328–31
   Google Scholar
• Browne J, Silver H, Martin R, Hart R, Margener M, Williams P. The use of clonidine in the treatment of neuroleptic induced tardive dyskinesia. J Clin Psychopharmacol 1986; 6: 88–92
   Google Scholar
• Gardos G, Cole JO. The treatment of tardive dyskinesias. Psychopharmacology: the fourth generation of progress, FE Bloom, D Kupfer. Raven, New York 1995; 1503–11
   Google Scholar
• Lohr JB. Oxygen radicals and neuropsychiatric illness. Arch Gen Psychiatry 1991; 48: 1097–106
   PubMed Web of Science ®Google Scholar
• Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo D. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 1993; 33: 700–6
   PubMed Web of Science ®Google Scholar
• Alphs LD, Davis JM. Cholinergic treatments for tardive dyskinesia. New directions in tardive dyskinesia research, J Bannet, RH Belmaker. Karger, Basel 1983; 168–86
   Google Scholar
• Gelenberg AJ, Dorer DJ, Wojcik JD, Falk WE, Brotman AW, Leahy L. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry 1990; 51: 149–53
   PubMed Web of Science ®Google Scholar
• Gardos G, Cole JO. Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 1983; 140: 200–2
   PubMed Web of Science ®Google Scholar
• Modell JG, Tandon R, Beresford TP. Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J Clin Psychopharmacol 1989; 9: 347–51
   Google Scholar
• Thaker GK, Ferraro TN, Hare TA, Tamminga CA. Pathophysiology and therapy of tardive dyskinesia: the GABA connection. Tardive dyskinesia-biological mechanisms and clinical aspects, ME Wolf, AD Mosnaim. American Psychiatric Press, Washington, DC 1988; 199–215
   Google Scholar
• Gunne LM, Levin ED, Johansson PE. The GABA theory of tardive dyskinesia. Tardive dyskinesia - biological mechanisms and clinical aspects, ME Wolf, AD Mosnaim. American Psychiatric Press, Washington, DC 1988; 29–38
   Google Scholar
• Borison RL, McLarnon MC, DeMartines N, Diamond B. Calcium channel antagonists: interaction with dopamine, schizophrenia and tardive dyskinesia. Tardive dyskinesia: biological mechanisms and clinical aspects, ME Wolf, AD Mosnaim. American Psychiatric Press, Washington 1988; 217–31
   Google Scholar
• Adler L, Duncan E, Reiter S, Angrist B, Peselow E, Rotrosen J. Effects of calcium-channel antagonists on tardive dyskinesia and psychosis. Psychopharmacol Bull 1988; 24: 421–5
   Google Scholar
• Loonen AJ, Verwey HA, Roels PR, Van Bavel LP, Doorschot CH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative double-blind, placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 39–42
   PubMed Web of Science ®Google Scholar
• Szymanski S, Munne R, Gordon MF, Lieberman J. A selective review of recent advances in the management of tardive dyskinesia. Psychiatr Ann 1993; 23: 209–15
   Web of Science ®Google Scholar
• Lohr JB, Cadet JL, Lohr MA, Larson L, Wash E, Wade L, et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988; 14: 291–6
   PubMed Web of Science ®Google Scholar
• Elkashef AM, Ruskin PE, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990; 147: 505–9
   PubMed Web of Science ®Google Scholar
• Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149: 773–7
   PubMed Web of Science ®Google Scholar
• Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150: 1405–7
   PubMed Web of Science ®Google Scholar
• Adler LA, Peselow E, Duncan E, Rosenthal M, Angrist B, Rotrosen J. Vitamin E treatment of tardive dyskinesia: 9 month clinical follow-up and measurement of effects on erythrocyte ghost membrane fluidity. Poster at the Thirty-first Annual Meeting of American College of Neuropsychopharmacology, San Juan, Puerto Rico, December, 161992
   Google Scholar
• Cole JO, Gardos G, Rapkin RM. Lithium carbonate in tardive dyskinesia and schizophrenia. Dyskinesia and affective disorder, G Gardos, DE Casey. American Psychiatric Press, Washington, DC 1984; 49–73
   Google Scholar
• Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1993; 13: 204–9
   PubMed Web of Science ®Google Scholar
• Hay DP, Hay L, Blackwell B, Spiro HR. ECT and tardive dyskinesia. J Geriatr Psychiatry Neurol 1990; 3: 106–9
   Google Scholar
• Glazier WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM. Estrogen replacement and tardive dyskinesia. Psychoendocrinology 1985; 10: 345–56
   Google Scholar
• Lang AE. Miscellaneous drug-induced movement disorders. Drug-induced movement disorders, AE Lang, WJ Weiner. Futura, Mt Kisco, New York 1992; 339–61
   Google Scholar
• Mouret J, Khomais M, Lemoine P. Low doses of insulin as a treatment of tardive dyskinesia: a double-blind, placebo-controlled study [Abstract]. Proceedings of the Seventeenth Annual Meeting of Collegium Internationale Neuro-Psychopharmacologicum. KyotoJapan 1990; 1: 155A
   Google Scholar
• Ganzini L, Casey DE, Hoffman WF, Heintz RT. Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull 1992; 28: 281–6
   Google Scholar
• Sandyk R, Fisher H. Serotonin in involuntary movement disorders. Int J Neurosci 1988; 42: 185–200
   PubMed Web of Science ®Google Scholar
• Burke RE. Neuroleptic-induced tardive dyskinesia variants. Drug-induced movement disorders, AE Lang, WJ Weiner. Futura, Mt Kisco, New York 1992; 167–98
   Google Scholar
• Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983; 33: 1255–61
   PubMed Web of Science ®Google Scholar
• Jankovic J, Arman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind placebo controlled study. Neurology 1987; 37: 616–23
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10
   PubMed Web of Science ®Google Scholar